Asset Details
Do you wish to reserve the book?
Anti-IL6R role in treatment of COVID-19-related ARDS
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Anti-IL6R role in treatment of COVID-19-related ARDS
Do you wish to request the book?
Anti-IL6R role in treatment of COVID-19-related ARDS
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Anti-IL6R role in treatment of COVID-19-related ARDS
2020
Overview
In this single arm study, patients with moderate to severe COVID-19 disease received one or two doses of tocilizumab (400 mg/dose) in addition to standard therapies used including lopinavir and methylprednisolone as reported in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (6th interim edition) [2]. Better outcomes were observed in non-intubated patients with elevated baseline level of IL-6 CRP, ferritin and LDH. [...]Italian Pharmaceutical Agency (AIFA) approved a Phase II trial in 330 patients with COVID-19 induced ARDS using tocilizumab started on March 19, 2020 (https://www.aifa.gov.it/documents/20142/1127901/TOCIVID-19_Protocol_v1.3_18Marzo2020.pdf/6843930d-9f31-185d-9812-29f02ebebd76) identified in USA as NCT04317092. [...]administration of tocilizumab has not prevented influenza vaccination immune response in patients with rheumatoid arthritis [6]. its role in patients infected with SARS-CoV-2 has not yet been fully studied and is awaiting completion of clinical trials under way. [...]that time, it seems plausible to speculate that the anti-IL6R mAb plays a protective role if given at the time of overly elevated immune response to the virus, thus preventing “anaphylactic toxicity”.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
